2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1560

Usefulness of 18F-FDG Positron Emission Tomography for Lymphoma Diagnosis in Patients with Primary Sjögren’S Syndrome
Abstract Number: 1561

B Lymphocyte Depletion Therapy with Rituximab in Primary Sjögren’s Syndrome: Indications , Effectiveness and Ultrasonographic Response
Abstract Number: 1562

Large Granular Lymphocyte Proliferations in Primary Sjögren’s Syndrome: An Iatrogenic Manifestation
Abstract Number: 1563

Risk of Overall Malignancies in Korean Patients with Primary Sjögren Syndrome
Abstract Number: 1564

Severe, Life-Threatening Phenotype of Primary Sjögren Syndrome: Clinical Characterization and Outcomes in 1580 Patients (GEAS-SS Registry)
Abstract Number: 1565

Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice
Abstract Number: 1566

Prevalence and Prognosis of Interstitial Lung Disease in a Large Cohort of Chinese Primary Sjögren’s Syndrome Patients
Abstract Number: 1567

The Risk Factors and Prognosis of Interstitial Lung Disease Associated with Primary Sjogren’s Syndrome: A Multi-Center Cohort Study
Abstract Number: 1568

Azathioprine and Mycophenolate for Management of Sjögren’s Syndrome-Related Interstitial Lung Disease: A Retrospective Cohort Study
Abstract Number: 1569

Diagnostic Performance of Labial Salivary Gland Biosy, Serological and Clinical Data in Sjogrens Syndrome. in Argentinian Multicenter
Abstract Number: 1570

Clinical Utility of a Second Minor Salivary Gland Biopsy in Patients with Suspected Sjögren’s Syndrome: A Retrospective Cohort Study
Abstract Number: 1571

RNA Sequencing Detection of Gene Dysregulation in Epithelial Cells Sorted from Salivary Gland Tissue Reveals Interesting Pathways Involved in Primary Sjögren’s Syndrome Pathophysiology
Abstract Number: 1572

Salivary Flow Rates and Oral Health Related Quality of Life Are Associated with Ultrasonographic Scoring of the Major Salivary Glands in Sjogren Syndrome
Abstract Number: 1573

Salivary Dysbiosis Correlates with Clinical Status of Anti-Ro Positive Mothers of Children with Neonatal Lupus
Abstract Number: 1574

Autoantibodies Present in Saliva from Sjogren’s Syndrome and Non-Sjogren’s Sicca Patients Are Not Detectible in Serum

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].